182181-38-0 Usage
Uses
Used in Pharmaceutical Industry:
3-Fluoro-4-piperazinylbenzenecarbonitrile is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and properties make it a valuable component in the development of new drugs.
Used in Antipsychotic Drug Development:
3-Fluoro-4-piperazinylbenzenecarbonitrile is used as a potential antipsychotic agent, given its capacity to modulate neurotransmitter systems involved in psychotic disorders, thereby offering a new avenue for the treatment of conditions such as schizophrenia.
Used in Analgesic Drug Development:
As an analgesic, 3-Fluoro-4-piperazinylbenzenecarbonitrile is used to develop drugs that can alleviate pain, potentially offering new options for the management of chronic and acute pain conditions.
Used in Antidepressant and Anti-Anxiety Drug Development:
3-Fluoro-4-piperazinylbenzenecarbonitrile is used as a potential candidate for the development of antidepressant and anti-anxiety medications, due to its potential to influence the neurochemical pathways associated with mood regulation and stress response.
Used in Neurological Disorder Treatment:
3-Fluoro-4-piperazinylbenzenecarbonitrile is being investigated for its potential use in treating a range of neurological disorders, leveraging its capacity to interact with the nervous system and potentially ameliorate symptoms associated with these conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 182181-38-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,2,1,8 and 1 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 182181-38:
(8*1)+(7*8)+(6*2)+(5*1)+(4*8)+(3*1)+(2*3)+(1*8)=130
130 % 10 = 0
So 182181-38-0 is a valid CAS Registry Number.
InChI:InChI=1/C11H12FN3/c12-10-7-9(8-13)1-2-11(10)15-5-3-14-4-6-15/h1-2,7,14H,3-6H2
182181-38-0Relevant academic research and scientific papers
QUINAZOLINONE COMPOUNDS AND RELATED COMPOUNDS
-
Paragraph 0167, (2021/08/27)
Disclosed are substituted quinazolinone compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions to treat diseases, disorders, or conditions such as those relating to unregulated protein functi
TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS
-
Page/Page column 542-543, (2020/10/21)
Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
-
Page/Page column 57, (2008/06/13)
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES
-
, (2008/06/13)
The present invention relates to imidazo[1,2-a]pyridine compounds of formula (1) STR1 which are dopamine D-4 antagonists and useful as anti-psychotic agents.
